Abstract
Years ago, we revealed a novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157, particular anti-ulcer peptide that heals different organs lesions when given as a therapy, native in human gastric juice while maintaining GI-tract mucosal integrity, already tested in trials (ulcerative colitis and now multiple sclerosis). The stomach cytoprotection is the most fundamental concept, stomach cell protection and endothelium protection are largely elaborated, but so far cell, protection and endothelium protection outside of the stomach were not implemented in the therapy. However, having managed these two points, stomach cell protection and endothelium protection, either one or together, even much more than standard cytoprotective agents do, BPC 157 employed large scale of its beneficial effects seen in various organs. Providing endothelium protection, BPC 157 was shown to prevent formation and reverse established thrombosis in anastomosed abdominal aorta as well as venous thrombosis after inferior caval vein occlusion, and attenuate bleeding prolongation and thrombocytopenia after amputation, without or with anticoagulants, or venous occlusion, and finally counteract effect of L-NAME and/or L- arginine. Now, with BPC 157 application, we reveal the third most important part of the cytoprotection concept: with the stomach cell and endothelium protection to recover mucosal integrity, BPC 157 as prototype cytoprotective agent should also control blood vessel function, depending upon injury, perforated defect or vessel obstruction. After a perforated injury (i.e., stomach), BPC 157 therapy activates blood vessels “running” towards defect. After obstruction (i.e., inferior caval vein), BPC 157 activates vessels “running” towards bypassing defect, collaterals functioning. Reestablished blood flow, and largely reversed injurious course may practically implement the cytoprotection concept.
Keywords: Stable gastric pentadecapeptide BPC 157, cytoprotection, stomach cells protection, organoprotection, endothelium protection, control of blood vessels function.
Current Pharmaceutical Design
Title:Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing
Volume: 24 Issue: 18
Author(s): Predrag Sikiric*, Rudolf Rucman, Branko Turkovic, Marko Sever, Robert Klicek, Bozo Radic, Domagoj Drmic, Mirjana Stupnisek, Marija Misic, Lovorka Batelja Vuletic, Katarina Horvat Pavlov, Ivan Barisic, Antonio Kokot, Marina Peklic, Sanja Strbe, Alenka Boban Blagaic, Ante Tvrdeic, Dinko Stancic Rokotov, Hrvoje Vrcic, Mario Staresinic and Sven Seiwerth
Affiliation:
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb,Croatia
Keywords: Stable gastric pentadecapeptide BPC 157, cytoprotection, stomach cells protection, organoprotection, endothelium protection, control of blood vessels function.
Abstract: Years ago, we revealed a novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157, particular anti-ulcer peptide that heals different organs lesions when given as a therapy, native in human gastric juice while maintaining GI-tract mucosal integrity, already tested in trials (ulcerative colitis and now multiple sclerosis). The stomach cytoprotection is the most fundamental concept, stomach cell protection and endothelium protection are largely elaborated, but so far cell, protection and endothelium protection outside of the stomach were not implemented in the therapy. However, having managed these two points, stomach cell protection and endothelium protection, either one or together, even much more than standard cytoprotective agents do, BPC 157 employed large scale of its beneficial effects seen in various organs. Providing endothelium protection, BPC 157 was shown to prevent formation and reverse established thrombosis in anastomosed abdominal aorta as well as venous thrombosis after inferior caval vein occlusion, and attenuate bleeding prolongation and thrombocytopenia after amputation, without or with anticoagulants, or venous occlusion, and finally counteract effect of L-NAME and/or L- arginine. Now, with BPC 157 application, we reveal the third most important part of the cytoprotection concept: with the stomach cell and endothelium protection to recover mucosal integrity, BPC 157 as prototype cytoprotective agent should also control blood vessel function, depending upon injury, perforated defect or vessel obstruction. After a perforated injury (i.e., stomach), BPC 157 therapy activates blood vessels “running” towards defect. After obstruction (i.e., inferior caval vein), BPC 157 activates vessels “running” towards bypassing defect, collaterals functioning. Reestablished blood flow, and largely reversed injurious course may practically implement the cytoprotection concept.
Export Options
About this article
Cite this article as:
Sikiric Predrag*, Rucman Rudolf , Turkovic Branko , Sever Marko , Klicek Robert , Radic Bozo, Drmic Domagoj , Stupnisek Mirjana , Misic Marija, Vuletic Batelja Lovorka , Pavlov Horvat Katarina , Barisic Ivan , Kokot Antonio , Peklic Marina, Strbe Sanja , Blagaic Boban Alenka , Tvrdeic Ante , Rokotov Stancic Dinko , Vrcic Hrvoje , Staresinic Mario and Seiwerth Sven , Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing, Current Pharmaceutical Design 2018; 24 (18) . https://dx.doi.org/10.2174/1381612824666180608101119
DOI https://dx.doi.org/10.2174/1381612824666180608101119 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Chronobiotics in the Resynchronization of the Sleep/Wake Cycle. Therapeutical Application in the Early Phases of Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting Hypertension: Superoxide Anions are Involved in Apelin-induced Long-term High Blood Pressure and Sympathetic Activity in the Paraventricular Nucleus
Current Neurovascular Research Role of the Autonomic Nervous System and Neuropeptides in the Development of Obesity in Humans: Targets for Therapy?
Current Pharmaceutical Design Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design The Clinical Pharmacology of Short Acting Analgo-Sedatives in Neonates
Current Clinical Pharmacology Whole Brain Atrophy and Sample Size Estimate via Iterative Principal Component Analysis for Twelve-month Alzheimer's Disease Trials
Neuroscience and Biomedical Engineering (Discontinued) Editorial
Current Nutrition & Food Science Training Psychiatrists in Cognitive Behavioral Psychotherapy: Current Status and Horizons
Current Psychiatry Reviews Potential of Combination of Bone Marrow Nucleated and Mesenchymal Stem Cells in Complete Spinal Cord Injury
Current Stem Cell Research & Therapy Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics Single-chain Fv Antibodies for Targeting Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research NLRP3 Inflammasome in the Pathophysiology of Hemorrhagic Stroke: A Review
Current Neuropharmacology Editorial [Hot Topic: Functions and Metabolism of Brain Nucleosides and their Metabolites (Guest Editors: Zsolt Kovacs & Arpad Dobolyi)]
Current Topics in Medicinal Chemistry Effect of Black Seed on Dextromethorphan O- and N-Demethylation in Human Liver Microsomes and Healthy Human Subjects
Drug Metabolism Letters Assessing Dopaminergic Neurotransmission with PET: Basic Theory and Applications in Alcohol Research
Current Medical Imaging Spatio-Temporal Fluctuations of Neural Dynamics in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Proteasome Regulators: Activators and Inhibitors
Current Medicinal Chemistry Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Current Topics in Medicinal Chemistry